NDA 208944 · Supernus Pharms
Gocovri
Amantadine Hydrochloride · Oral · Influenza A M2 Protein Inhibitor
OrphanLast checked: Nov 20, 2026Latest source record: Jul 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Aug 24, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
324
86 Phase 3, 21 recruiting
FAERS reports
15,734
9,513 serious, 1,674 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 5, 2026.
GOCOVRI ® is indicated: For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes GOCOVRI ® is indicated: For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications ( 1 ) As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes ( 1 )
Mechanism: The mechanism by which amantadine exerts efficacy in the treatment of dyskinesia in patients with Parkinson's disease or as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes is unknown. Amantadine is a weak uncompetitive antagonist of the NMDA receptor. Amantadine has not been shown to possess direct anticholinergic activity in animal studies; however, it exhibits anticholinergic-like side effects such as dry mouth, urinary retention, and constipation in humans. Amantadine may have direct and indirect effects on dopamine neurons; it...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 1, 2021 Supplement 4 · Efficacy OrphanLabelLetter
- Aug 24, 2017 Original approval · Type 3 - New Dosage Form OrphanLabelLetterReview
2 products under this application
- GOCOVRI · AMANTADINE HYDROCHLORIDE EQ 137MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- GOCOVRI · AMANTADINE HYDROCHLORIDE EQ 68.5MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amantadine" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Evaluation of S (+) - Ketamine in AdultsPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04837170 · 12,000 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2022
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: Postoperative Pain; Adults; Anesthesia
- Safety and Efficacy Evaluation of S (+) - Ketamine in ChildrenPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04834427 · 3,000 participants (planned) · Start Apr 20, 2022 · Primary completion Dec 1, 2024
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: S-ketamine; Esketamine; Acute Pain and 6 more
Sites: Beijing, China
- Pragmatic Trial of Obsessive-compulsive DisorderPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT04539951 · 1,600 participants (planned) · Start Sep 22, 2020 · Primary completion Jun 30, 2027
Drug: Sertraline 200 milligram(mg); Sertraline 300 milligram(mg) and 4 more · For: Obsessive-Compulsive Disorder
Sites: Shanghai, China
- Memantine in Patients With Chronic GlaucomaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00168350 · 1,179 participants · Start Mar 2000 · Primary completion Sep 2006
Drug: memantine · For: Open-Angle Glaucoma
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised TrialPivotal-lookingRecruiting
University of EdinburghAcademic, hospital or other
NCT04302870 · 1,150 participants (planned) · Start Feb 27, 2020 · Primary completion Dec 2030
Drug: Memantine Hydrochloride Oral Solution; Trazodone Hydrochloride oral solution and 4 more · For: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Sites: Portadown, United Kingdom; Aberdeen, United Kingdom; Birmingham, United Kingdom · 22 sites in all
- Memantine in Patients With Chronic GlaucomaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00141882 · 1,119 participants · Start Mar 1999 · Primary completion Jan 2006
Drug: memantine · For: Open-Angle Glaucoma
Forest LaboratoriesAbbVie (ABBV)
NCT01592786 · 906 participants · Start Jun 2012 · Primary completion Jul 2013
Drug: Memantine Hydrochloride (HCl) · For: Autism Spectrum Disorder (ASD); Autism; Autistic Disorder and 4 more
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 118 sites in all
- Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for ComplicationsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01227967 · 881 participants · Start Sep 2010 · Primary completion May 2, 2016
Drug: Amantadine, Ribavirin, Oseltamivir; Oseltamivir · For: Influenza
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 91 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fall1,821
- hallucination1,356
- drug ineffective1,295
- fatigue1,118
- dyskinesia1,114
- dizziness962
- gait disturbance922
- death898
- tremor819
- nausea694
- parkinson^s disease678
- asthenia663
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 113 |
| 2006 | 3 |
| 2007 | 6 |
| 2008 | 24 |
| 2009 | 41 |
| 2010 | 95 |
| 2011 | 37 |
| 2012 | 148 |
| 2013 | 406 |
| 2014 | 475 |
| 2015 | 643 |
| 2016 | 888 |
| 2017 | 1,095 |
| 2018 | 1,455 |
| 2019 | 1,436 |
| 2020 | 1,599 |
| 2021 | 1,593 |
| 2022 | 1,471 |
| 2023 | 959 |
| 2024 | 1,055 |
| 2025 | 1,223 |
| 2026 | 952 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gocovri (Amantadine HCl)
2024 spending
$99.8M
Beneficiaries
4,906
30,705 claims
Per beneficiary
$20,351
$55.42 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $53,349,153 |
| 2021 | $70,562,668 |
| 2022 | $82,318,372 |
| 2023 | $91,875,721 |
| 2024 | $99,842,782 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis.
Gao Y, Zhao Y, Liu M, et al. · JAMA Intern Med 2025 · Network Meta-Analysis, Systematic Review
- Pharmacological Treatment of Agitation and/or Aggression in Patients With Traumatic Brain Injury: A Systematic Review of Reviews.
Rahmani E, Lemelle TM, Samarbafzadeh E, et al. · J Head Trauma Rehabil 2021 · Systematic Review
- Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.
Zhao Y, Gao Y, Guyatt G, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Influenza.
Jefferson T · BMJ Clin Evid 2009 · Systematic Review
- Multiple sclerosis.
Nicholas R, Chataway J · BMJ Clin Evid 2009 · Systematic Review
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Supernus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.